Enzo Biochem, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment reporting (Detail) - Operating results of the reportable segments

Segment reporting (Detail) - Operating results of the reportable segments (USD $) In Thousands, unless otherwise specified	3 Months Ended								12 Months Ended
	Jul. 31, 2012	Apr. 30, 2012	Jan. 31, 2012	Oct. 31, 2011	Jul. 31, 2011	Apr. 30, 2011	Jan. 31, 2011	Oct. 31, 2010	Jul. 31, 2012	Jul. 31, 2011	Jul. 31, 2010
Revenues:
Clinical laboratory services									$ 59,403	$ 52,762	$ 44,178
Product revenues									37,722	41,830	43,111
Royalty and license fee income									5,958	7,437	9,793
Total revenues									103,083	102,029	97,082
Operating expenses:
Cost of clinical laboratory services									36,305	31,682	29,570
Cost of product revenues									19,668	22,137	22,547
Research and development									6,293	7,806	9,704
Selling, general and administrative									47,928	45,191	48,395
Provision for uncollectible accounts receivable									5,104	4,431	3,480
Legal									3,724	3,710	1,746
Litigation settlement											3,698
Impairment charges									24,540
Total operating expenses									143,562	114,957	119,140
Operating (loss) income									(40,479)	(12,928)	(22,058)
Other income (expense)
Interest									21	11	19
Other									77	45	44
Foreign exchange gain (loss)									(540)	49	(266)
Income (loss) before income taxes	(29,074)	(3,445)	(4,076)	(4,326)	(4,199)	(2,002)	(5,562)	(1,060)	(40,921)	(12,823)	(22,261)
Depreciation and amortization included above									4,477	4,469	4,269
Share-based compensation included in above:
Share-based compensation									719	1,049	1,170
Capital expenditures									1,364	1,223	3,251
Clinical Labs [Member] \| Cost of Clinical Laboratory Services [Member]
Share-based compensation included in above:
Share-based compensation									10	10	12
Clinical Labs [Member] \| Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation									49	61	78
Clinical Labs [Member]
Revenues:
Clinical laboratory services									59,403	52,762	44,178
Total revenues									59,403	52,762	44,178
Operating expenses:
Cost of clinical laboratory services									36,305	31,682	29,570
Research and development									299
Selling, general and administrative									20,856	18,426	18,503
Provision for uncollectible accounts receivable									4,987	4,415	3,432
Legal									262	387	222
Total operating expenses									62,709	54,910	51,727
Operating (loss) income									(3,306)	(2,148)	(7,549)
Other income (expense)
Interest									(5)	(5)
Other									28	30	46
Income (loss) before income taxes									(3,283)	(2,123)	(7,503)
Depreciation and amortization included above									1,092	1,012	982
Share-based compensation included in above:
Share-based compensation									59	71	90
Capital expenditures									921	834	1,728
Life Sciences [Member] \| Research and Development Expense [Member]
Share-based compensation included in above:
Share-based compensation									4	14	14
Life Sciences [Member] \| Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation									59	84	114
Life Sciences [Member]
Revenues:
Product revenues									37,722	41,830	43,111
Royalty and license fee income									5,958	7,437	9,793
Total revenues									43,680	49,267	52,904
Operating expenses:
Cost of product revenues									19,668	22,137	22,547
Research and development									4,308	5,784	7,202
Selling, general and administrative									18,305	17,855	19,800
Provision for uncollectible accounts receivable									117	16	48
Legal									536	726	145
Impairment charges									24,540
Total operating expenses									67,474	46,518	49,742
Operating (loss) income									(23,794)	2,749	3,162
Other income (expense)
Interest									23	2	(5)
Other									27	(3)	(8)
Foreign exchange gain (loss)									(540)	49	(266)
Income (loss) before income taxes									(24,284)	2,797	2,883
Depreciation and amortization included above									3,217	3,282	3,110
Share-based compensation included in above:
Share-based compensation									63	98	128
Capital expenditures									443	389	1,450
Therapeutics [Member]
Operating expenses:
Research and development									1,686	2,022	2,502
Total operating expenses									1,686	2,022	2,502
Operating (loss) income									(1,686)	(2,022)	(2,502)
Other income (expense)
Income (loss) before income taxes									(1,686)	(2,022)	(2,502)
Depreciation and amortization included above									43	47	52
Share-based compensation included in above:
Capital expenditures											11
All Other Segments [Member] \| Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation									597	880	952
All Other Segments [Member]
Operating expenses:
Selling, general and administrative									8,767	8,910	10,092
Legal									2,926	2,597	1,379
Litigation settlement											3,698
Total operating expenses									11,693	11,507	15,169
Operating (loss) income									(11,693)	(11,507)	(15,169)
Other income (expense)
Interest									3	14	24
Other									22	18	6
Income (loss) before income taxes									(11,668)	(11,475)	(15,139)
Depreciation and amortization included above									125	128	125
Share-based compensation included in above:
Share-based compensation									597	880	952
Capital expenditures											62
Cost of Clinical Laboratory Services [Member]
Share-based compensation included in above:
Share-based compensation									10	10	12
Research and Development Expense [Member]
Share-based compensation included in above:
Share-based compensation									4	14	14
Selling, General and Administrative Expenses [Member]
Share-based compensation included in above:
Share-based compensation									$ 705	$ 1,025	$ 1,144